Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059322 | 0.90 | BCHE (0.63) | GRIN2DGRIN2CMAOABCHEKMT2A | |
| SCHEMBL12043913 | 0.89 | GRIN2D (0.70) | GRIN2DGRIN2CMAOABCHEKMT2A | |
| SCHEMBL12044324 | 0.85 | RAB9A (0.48) | GRIN2DGRIN2CBCHEKMT2ANPC1 | |
| SCHEMBL12044319 | 0.83 | DHPS (0.60) | GRIN2DGRIN2CMAOAKMT2AMEN1 | |
| SCHEMBL12043935 | 0.82 | GRIN2D (0.79) | GRIN2DGRIN2CKMT2AMEN1NPC1 | |
| SCHEMBL12059796 | 0.76 | KEAP1 (0.51) | KMT2AMEN1NPC1RAB9AHSD17B10 | |
| SCHEMBL12044287 | 0.74 | L3MBTL1 (0.56) | GRIN2DGRIN2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12043947 | 0.72 | GRIN2D (0.67) | GRIN2DGRIN2CKMT2AMEN1NPC1 | |
| SCHEMBL12059477 | 0.72 | KMT2A (0.45) | GRIN2DGRIN2CMAOAKMT2AMEN1 | |
| SCHEMBL12043912 | 0.71 | GRIN2D (1.00) | GRIN2DGRIN2CKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250092395-A1 | A GLUN2D INHIBITOR FOR USE IN THE TREATMENT OR RELAPSE PREVENTION OF A DEPRESSIVE EPISODE | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-03-20 | — | — | US | disclosed |
| EP-4469042-A1 | A GLUN2D INHIBITOR FOR USE IN THE TREATMENT OR RELAPSE PREVENTION OF A DEPRESSIVE EPISODE | Albert-Ludwigs-Universität Freiburg (DE) | 2024-12-04 | — | — | EP | disclosed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118785903-A | GLUN2D inhibitors for the treatment or relapse prevention of depressive episodes | 阿尔伯特-路德维希-弗莱堡大学 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023144163-A1 | A GLUN2D INHIBITOR FOR USE IN THE TREATMENT OR RELAPSE PREVENTION OF A DEPRESSIVE EPISODE | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-08-03 | — | — | WO | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | GRIN2D 8/4885GRIN2C 5/4885MAOA 628/4885 |
| US-20250092395-A1 | A GLUN2D INHIBITOR FOR USE IN THE TREATMENT OR RELAPSE PREVENTION OF A DEPRESSIVE EPISODE | GRIN2A, GRIN2B, GRIN2C | GRIN2D 7/4885GRIN2C 3/4885MAOA 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.